ADVM
NASDAQAdverum Biotechnologies Inc.
Adverum Biotechnologies Inc. (ADVM) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for ADVM in the last 30 days. The most recent was published Dec 19, 2025.
Latest news
25 items- SECSEC Form 15-12G filed by Adverum Biotechnologies Inc.15-12G - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form EFFECT filed by Adverum Biotechnologies Inc.EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form EFFECT filed by Adverum Biotechnologies Inc.EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form EFFECT filed by Adverum Biotechnologies Inc.EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- INSIDERCEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERChief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERSEC Form 4 filed by Director Hong Soo4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERSEC Form 4 filed by Director Whitcup Scott M4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERSEC Form 4 filed by Director Tuckson Reed Vaughn4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERDirector Svoronos Dawn closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERDirector Scopa James Paul closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson, C. David4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERDirector Lupher, Jr. Mark L. closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERDirector Machado Patrick closing all direct ownership in the company (SEC Form 4)4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- INSIDERSEC Form 4 filed by Director Kiss Szilard4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Adverum Biotechnologies Inc.SCHEDULE 13D/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adverum Biotechnologies Inc.SCHEDULE 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)
- INSIDERSEC Form 4 filed by Large owner Frazier Life Sciences Public Fund, L.P.4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)
- SECSEC Form S-8 POS filed by Adverum Biotechnologies Inc.S-8 POS - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form S-8 POS filed by Adverum Biotechnologies Inc.S-8 POS - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form S-8 POS filed by Adverum Biotechnologies Inc.S-8 POS - Adverum Biotechnologies, Inc. (0001501756) (Filer)
- SECSEC Form S-8 POS filed by Adverum Biotechnologies Inc.S-8 POS - Adverum Biotechnologies, Inc. (0001501756) (Filer)
ADVM FAQ
8 questionsWhat does Adverum Biotechnologies Inc. do?
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc...What is the latest news on ADVM?
Quantisnow has not tracked any new filings, ratings or press releases for ADVM in the last 30 days. The most recent wire item was published on December 19, 2025.Where does ADVM stock trade?
Adverum Biotechnologies Inc. (ADVM) is listed on NASDAQ.What sector and industry is ADVM in?
Adverum Biotechnologies Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Adverum Biotechnologies Inc. go public?
Adverum Biotechnologies Inc. (ADVM) completed its IPO in 2014.What are analysts saying about ADVM?
Across the last 7 analyst actions on Adverum Biotechnologies Inc., there was 1 upgrade and 3 downgrades. The most recent action was from H.C. Wainwright: Neutral on 2025-11-17.What companies are similar to ADVM?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ADVM side-by-side with any of them on Quantisnow.How can I track ADVM on Quantisnow?
Quantisnow aggregates Adverum Biotechnologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADVM to receive live email and push alerts on every new disclosure.